Person:
ÇAKIR, FATMA BETÜL

Profile Picture
Google ScholarScopusORCIDPublons
Status
Kurumdan Ayrılmıştır.
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
FATMA BETÜL
Last Name
ÇAKIR
Name
Email Address
Birth Date

Filters

2022 - 20244
Reset filters

Settings

Type: article × Subject: Child Health and Diseases × Subject: Clinical Medicine (MED) ×

Search Results

Now showing 1 - 4 of 4
  • No Thumbnail Available
    PublicationMetadata only
  • No Thumbnail Available
    PublicationMetadata only
    EARTHQUAKE DISASTER AND ITS' ACUTE EFFECT ON PEDIATRIC HEMATOLOGY AND ONCOLOGY.IN TURKIYE; TURKISH PEDIATRIC ONCOLOGY GROUP-TPOG QUESTIONARE STUDY
    (2023-11-01) TAÇYILDIZ N.; İNCESOY ÖZDEMİR S.; Kupeli B.; Cemaloglu M.; Acipayam C.; Oncel K.; Akinel A. N.; Karabel N.; Coskun C.; SEZGİN G.; et al.; ÇAKIR, FATMA BETÜL
  • No Thumbnail Available
    PublicationMetadata only
    KAPOSIFORM HEMANGIOENDOTHELIOMA AND REFRACTORY KASABACH-MERRITT PHENOMENON TREATED WITH SIROLIMUS
    (2023-11-01) EREN T.; ÇAKIR F. B.; ÇAKIR, FATMA BETÜL
  • No Thumbnail Available
    PublicationMetadata only
    Comparison of clinical features of cystic fibrosis patients eligible but not on CFTR modulators to ineligible for CFTR modulators
    (2024-01-01) Nayır Büyükşahin H.; EMİRALİOĞLU ORDUKAYA N.; Yalçın E.; Şen V.; Selimoğlu Şen H.; Arslan H.; Başkan A. K.; Çakır F. B.; Koray C. F.; Yılmaz A. İ.; et al.; ÇAKIR, FATMA BETÜL; OGUN, HAMZA; YAZAN, HAKAN; ÇAKIR, ERKAN
    Introduction: Cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs target the underlying defect and improve CFTR function. They are a part of standard care in many countries, but not all patients are eligible for these drugs due to age and genotype. Here, we aimed to determine the characteristics of non-eligible patients for CFTR modulators in the CF registry of Turkey (CFRT) to highlight their clinical needs. Methods: This retrospective cohort study included CF patient data from the CFRT in 2021. The decision of eligibility for the CFTR modulator was determined according to the ‘Vertex treatment-Finder\" on the Vertex® website. Demographic and clinical characteristics of patients were compared between eligible (group 1) and ineligible (group 2) groups for CFTR modulators. Results: Among the study population (N = 1527), 873 (57.2%) were in group 1 and 654 (42.8%) were in group 2. There was no statistical difference between groups regarding sex, meconium ileus history, diagnoses via newborn screening, FEV1 z-score, CF-associated complications, organ transplant history, and death. Patients in group 2 had a higher incidence of pancreatic insufficiency (87.7% vs. 83.2%, p =.010), lower median height z-scores (−0.87 vs. −0.55, p <.001), lower median body mass index z-scores (−0.65 vs. −0.50, p <.001), longer days receiving antibiotics due to pulmonary exacerbation (0 [interquartile range, IQR: 0–2] vs. 0 [IQR: 0–7], p = 0.001), and more non-invasive ventilation support (2.6% vs. 0.9%, p = 0.008) than patients in group 1. Conclusion: The ineligible group had worse clinical outcomes than the eligible group. This highlights their need for life-changing drugs to improve clinical outcomes.